$SYBX

The merger will create a publicly traded company focused on advancing Caldera's lead inflammatory bowel disease therapy, with financing expected to fund operations into 2029. Key Investor Takeaways Synlogic (USOTC:SYBX) agreed to merge with privately held Caldera Therapeutics in an all-stock transaction to create a new public company. A concurrent upsized private placement is expected to raise approximately $278 million to support development of CLD-423 through Phase 2 clinical trials.

Synlogic and Caldera Therapeutics agreed to merge in an all-stock deal creating a Nasdaq-listed biotech under the Caldera name, targeting ticker CALD. Caldera secured $278 million in private placement funding plus existing cash to fund operations into 2029. Proceeds support Phase 2 trials of CLD-423 in ulcerative colitis and Crohn’s disease; Phase 1 data show good tolerability and >40-day half-life.

Synlogic (SYBX) agreed to merge with Caldera Therapeutics (Caldera) in an all-stock deal. The combined company will be Caldera Therapeutics, a new holding company, and intends to list on Nasdaq under ticker CALD. A concurrent private placement is expected to raise about $278 million gross to fund Phase 2 CLD-423 and operations into 2029.

SYNLOGIC, INC. (SYBX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 d91010dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: CALDERA THERAPEUTICS, INC.; SYNLOGIC, INC.; SONIC HOLDCO, INC.; YELLOWSTONE MERGER SUB, INC.; and SONIC MERGER SUB, INC.; Dated as of July 28, 2026 TABLE OF CONTENTS Page ARTICLE I DEFIN

Synlogic, Inc. has filed an amendment to its 2025 Annual Report (10-K/A) to provide detailed information on its board of directors, executive and director compensation, corporate governance, and major shareholders. The filing reveals that the company's Board consists of four independent directors, and as of March 31, 2026, Synlogic had only one full-time employee focused on strategic transactions. Key financial figures include Principal Executive and Financial Officer Mary Beth Dooley's 2025 compensation of $335,500 and audit fees paid to KPMG LLP totaling $365,000 for the same year.